Aurora Cannabis Inc.

NASDAQ:ACB

Drug Manufacturers - Specialty & Generic

Healthcare
$4.40 +0.51%

+$0.02 today

Market cap
$289.28M
Beta
1.34
P/E (TTM)
-3.2
EPS (TTM)
-$1.31
52W Low $2.73High $6.67

Volume 0.92M

Average 1.00M

ACB EBITDA Margin

EBITDA as a percentage of revenue.

Aurora Cannabis Inc.NASDAQ: ACB

EBITDA Margin · Q4 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to -66.1%

EBITDA Margin was -66.1% in Q4 FY2026, down 53.4 pp from a year earlier. On a trailing-twelve-month basis it was 3.4%, down 11.6 pp year over year. Over 3 fiscal years it widened by 14.0 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 3 analysts of -0.9% for the fiscal year ending Mar 2027, up from -46.4% in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-66.1%-75.2 pp QoQ
Last fiscal yearMar 2026
-46.4%-61.3 pp YoY
LTMMar 2026
3.4%-11.6 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-53.4 pp-56.1 pp-2.7 pp
1 year-61.3 pp+45.5 pp+106.8 pp
3 years+14.0 pp+60.3 pp+46.3 pp
5 years+61.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2026
-46.4%
Year-over-year change
-61.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ACB compares with its peers on the latest reported figures

  • ACB's LTM Mar 2026 EBITDA Margin of 3.4% is the 2nd highest of the 11 companies compared; the peer median is -12.9%.
  • Its year-over-year change of -11.6 pp is the 9th highest of 10, against a peer median of +18.3 pp.
  • Over three fiscal years its change of +14.0 pp compares with a peer median of +19.4 pp.
ACB Competitors Peer median
EBITDA Margin for ACB and competitors
Company Period LTM level YoY 3-year change
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 202657.3% +32.9 pp-28.3 pp
ACBAurora Cannabis Inc.LTM Mar 20263.4% -11.6 pp+14.0 pp
OGIOrganigram Global Inc.LTM Mar 20262.1% -1.6 pp—
LFCRLifecore Biomedical, Inc.LTM Mar 2026-0.8% —-18.4 pp
HITIHigh Tide Inc.LTM Apr 2026-0.9% -5.9 pp+7.1 pp
LFMDLifeMD, Inc.LTM Mar 2026-1.9% -3.3 pp+31.6 pp
TKNOAlpha Teknova, Inc.LTM Mar 2026-23.8% +18.3 pp+37.0 pp
CGCCanopy Growth CorporationLTM Mar 2026-65.7% +112.4 pp+874.7 pp
EDITEditas Medicine, Inc.LTM Mar 2026-258.7% +387.8 pp+719.4 pp
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-843.9% -542.0 pp-540.2 pp
BIOABioAge Labs, Inc.LTM Mar 2026-864.8% +3922.9 pp—
Peer median (excluding ACB) -12.9%+18.3 pp+19.4 pp

Competitors are the stored peer set for ACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2022
Jun 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue221.34M223.8M270.28M343.29M321.42M
Cost of Revenue200.11M209.02M138.82M155.69M304.67M
Gross Profit21.23M14.78M131.46M187.61M16.75M
Gross Margin9.6%6.6%48.6%54.6%5.2%
Research & Development10.39M5.77M3.57M3.68M6.01M
Selling, General & Admin188.99M170.48M156.88M166.47M173.95M
Operating Expenses252.67M221.98M177.91M182.66M179.96M
Depreciation & Amortization93.66M52.59M33.07M22.55M14.23M
EBITDA(1.55B)(135M)(12.34M)51.35M(148.99M)
EBITDA Margin-702.4%-60.3%-4.6%15.0%-46.4%
Operating Income(231.45M)(207.19M)(46.45M)4.95M(163.21M)
Operating Margin-104.6%-92.6%-17.2%1.4%-50.8%
Interest Income4.51M19M12.81M11.51M5.86M
Interest Expense71.81M39.46M14.19M8.42M1.81M
Other Income / Expenses(1.49B)(576.51M)(13.15M)15.43M106.54M
Income Before Tax(1.72B)(783.7M)(59.6M)20.38M(56.67M)
Pre-Tax Margin-777.1%-350.2%-22.1%5.9%-17.6%
Income Tax Expense(2.14M)16.55M(554K)4.62M2.1M
Net Income(1.72B)(816.63M)(69.33M)1.59M(122.07M)
Net Margin-776.0%-364.9%-25.6%0.5%-38.0%
EPS (Basic)(79.92)(8.17)(1.28)0.03(2.15)
EPS (Diluted)(79.92)(8.17)(1.28)0.03(2.15)
Weighted Avg Shares21.49M32.27M51.26M54.88M56.71M
Weighted Avg Shares (Diluted)21.49M32.27M51.26M55.75M56.71M

Aurora Cannabis Inc.

NASDAQ:ACB

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.